Anzeige
Mehr »
Montag, 06.10.2025 - Börsentäglich über 12.000 News
Das Paradox-Becken beweist seine Stärke - und American Critical Minerals sitzt direkt darauf
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 883035 | ISIN: US8816242098 | Ticker-Symbol: TEV
Tradegate
03.10.25 | 18:53
17,350 Euro
+0,87 % +0,150
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD Chart 1 Jahr
5-Tage-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
16,95017,10005.10.
16,90017,20003.10.

Aktuelle News zur TEVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoUBS Maintains its Buy Rating on Teva Pharmaceutical Industries Limited (TEVA); Raises Its Price Target to $26.0039
DoTruist Securities Reaffirms Its Buy Rating for Teva Pharmaceutical Industries Limited (TEVA)16
29.09.Teva Pharmaceutical: Teva's Journey to 100% Renewable Electricity: Bold Targets, Bold Solutions335NORTHAMPTON, MA / ACCESS Newswire / September 29, 2025 / Reaching 100% renewable electricity in 10 years - that's a bold target. And bold targets require bold solutions.One way Teva is working toward...
► Artikel lesen
TEVA Aktie jetzt für 0€ handeln
25.09.DelveInsight Business Research, LLP: TL1A Binder Market Set to Expand by 2034 with Key Players Such as Merck, Roche, Teva Pharmaceuticals, Sanofi, and Others Driving Multi-Indication Advancements | DelveInsight873The TL1A inhibitor market is rapidly advancing, driven by significant investments from major biopharmaceutical companies and growing confidence in its potential to transform autoimmune disease...
► Artikel lesen
25.09.Teva Pharmaceutical Industries Ltd: Teva Releases Q3 2025 Aide Memoire372TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the "Investors" page on its...
► Artikel lesen
25.09.Teva Pharmaceutical Industries Ltd: Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025385TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial...
► Artikel lesen
24.09.UBS hebt Kursziel für Teva Pharm wegen Austedo-Ausblick auf 26 US-Dollar an84
23.09.Bausch, Teva face lawsuit for delay in generic version of Xifaxan15
23.09.Teva and Medincell's Risperidone LAI Approved in Canada as LONGAVO348Regulatory News: Medincell (Paris:MEDCL): Teva Canada Limited, a subsidiary of Medincell's partner Teva Pharmaceutical Industries Ltd., has received regulatory approval for risperidone LAI...
► Artikel lesen
23.09.Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?24
23.09.Truist Securities reiterates Buy rating on Teva Pharma stock, maintains $25 price target10
23.09.Truist Securities bestätigt "Buy"-Rating für Teva Pharm Aktie und Kursziel von 25 US-Dollar21
23.09.Goldman Sachs bestätigt Kaufempfehlung für Teva Pharm nach positiven Studiendaten62
23.09.Teva Pharma stock gets Buy rating from Goldman Sachs on positive drug data19
22.09.Teva Pharm: Langzeitstudie zu Olanzapin-Depot-Injektion zeigt keine Fälle von PDSS46
22.09.Teva's olanzapine LAI shows no PDSS events in long-term trial data19
21.09.Teva Pharm: Langzeit-Olanzapin verursacht in Phase-3-Studie kein Post-Injektions-Syndrom45
21.09.Teva reports no PDSS events with olanzapine LAI in schizophrenia trial4
21.09.Teva Pharmaceutical Industries Ltd: Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction672Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) extended-release tabletsPatients reported high...
► Artikel lesen
21.09.Teva Pharmaceutical Industries Ltd: New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed793Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic...
► Artikel lesen
Weiter >>
271 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,1,1